Proteostasis Therapeutics, Inc. (PTI) News
Filter PTI News Items
PTI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PTI News From Around the Web
Below are the latest news stories about Proteostasis Therapeutics Inc that investors may wish to consider to help them evaluate PTI as an investment opportunity.
Here's Why We're Watching Proteostasis Therapeutics' (NASDAQ:PTI) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split RatioProteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at 9:00 a.m. Eastern Time on December 22, 2020 (the "Special Meeting"), its stockholders approved all of the proposals related to the merger (the "Merger") as contemplated by the Agreement and Plan of Merger and Reorganization, dated August 22, 2020, as amended, by and among Proteostasis, Yumanity Holdings, LLC ("Holdings"), Yumanity Therapeutics, Inc. ("Yumanity"), a wholly-owned subsidiary of Holdings, and Pangolin Merger Sub, a wholly-owned subsidiary of Proteostasis ("Merger Sub") (the "Merger Agreement"), including (i) the issuance of Proteostasis common stock in the Merger i... |
Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with ProteostasisLeading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis plans to adjourn its special meeting of stockholders to December 22, 2020BOSTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, and Proteostasis Therapeutics, Inc. (Nasdaq: PTI) today announced that Proteostasis has entered into a definitive agreement for the sale of its Common Stock in a private placement led by Fidelity Management & Research Company, LLC and Invus and including participation from Sphera Biotech, Stonepi... |
Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm – MVC, PTI, CGIX, STNDNEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: MVC Capital, Inc. (NYSE: MVC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Barings BDC, Inc. Under the terms of the merger agreement, MVC Capital shareholders will receive 0.94024 shares of Barings BDC and $0.39492 in cash for each share of MVC Capital stock. If you are an MVC Capital shareholder, click here to learn more about your legal rights and options.Proteostasis Therapeutics, Inc. (NASDAQ: PTI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Yumanity Therapeutics. If you are a Proteostasis sharehol... |
Do Hedge Funds Love Proteostasis Therapeutics, Inc. (PTI)?The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […] |
WeissLaw LLP Reminds CCR, TCO, UROV, and PTI Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Proteostasis Therapeutics Reports Third Quarter 2020 Financial ResultsProteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2020. |
SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Investigations; Investors are Encouraged to Contact the Firm – CBMG, MVC, PTI, CGIXNEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. If you are a Cellular Biomedicine shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/cellular-biomedicine-group-inc-cbmg-stock-merger/.MVC Capital, Inc. (NYSE: MVC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Barings BDC, Inc. Under the terms of the merger agreement, ... |
SHAREHOLDER ALERT: WeissLaw LLP Reminds BMHC, SFBK, WPX, and PTI Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Proteostasis Therapeutics (PTI) Sees Hammer Chart Pattern: Time to Buy?Proteostasis Therapeutics (PTI) has been struggling lately, but the selling pressure may be coming to an end soon. |